XFOR X4 Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XFOR

Price (delayed)

$3.11

Market cap

$308.35M

P/E Ratio

155.5

Dividend/share

N/A

EPS

$0.02

Enterprise value

$190.48M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 27

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system. Our lead clinical candidate is mavorixafor, ...

Highlights
The EPS has soared by 101% since the previous quarter and by 100% year-on-year
X4 Pharmaceuticals's net income has increased by 12% YoY and by 10% from the previous quarter
The revenue has surged by 76% since the previous quarter but it has dropped by 52% year-on-year
X4 Pharmaceuticals's gross profit has soared by 75% from the previous quarter but it has plunged by 53% YoY
The equity has contracted by 8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.x4pharma.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of XFOR

XFOR stock price

How has the X4 Pharmaceuticals stock price performed over time
Intraday
-9.33%
1 week
-11.4%
1 month
-23.02%
1 year
-9.86%
YTD
-22.25%
QTD
-33.4%

Financial performance

How have X4 Pharmaceuticals's revenue and profit performed over time
Revenue
$15.85M
Gross profit
$12.92M
Operating income
-$87.91M
Net income
-$90.14M
Gross margin
81.5%
Net margin
-568.8%
The net margin has plunged by 83% YoY but it has grown by 49% from the previous quarter
The revenue has surged by 76% since the previous quarter but it has dropped by 52% year-on-year
X4 Pharmaceuticals's gross profit has soared by 75% from the previous quarter but it has plunged by 53% YoY
XFOR's operating margin has dropped by 72% year-on-year but it is up by 49% since the previous quarter

Price vs fundamentals

How does XFOR's price correlate with its fundamentals

Growth

What is X4 Pharmaceuticals's growth rate over time

Valuation

What is X4 Pharmaceuticals stock price valuation
P/E
155.5
P/B
1.89
P/S
24.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.02
The EPS has soared by 101% since the previous quarter and by 100% year-on-year
The stock's price to book (P/B) is 84% less than its 5-year quarterly average of 13.2 but 9% more than its last 4 quarters average of 1.9
The equity has contracted by 8% from the previous quarter
The revenue has surged by 76% since the previous quarter but it has dropped by 52% year-on-year
The P/S is 4.8% more than the last 4 quarters average of 26.1

Efficiency

How efficient is X4 Pharmaceuticals business performance
The company's return on equity has surged by 83% YoY and by 34% QoQ
The ROS has dropped by 82% year-on-year but it rose by 49% since the previous quarter
XFOR's return on assets is up by 49% year-on-year and by 23% since the previous quarter
XFOR's return on invested capital is up by 8% since the previous quarter and by 4.1% year-on-year

Dividends

What is XFOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XFOR.

Financial health

How did X4 Pharmaceuticals financials performed over time
XFOR's total assets is 159% greater than its total liabilities
XFOR's total assets has soared by 141% year-on-year but it is down by 6% since the previous quarter
The company's current ratio rose by 11% QoQ
The debt is 50% less than the equity
X4 Pharmaceuticals's debt to equity has plunged by 97% YoY but it has increased by 9% from the previous quarter
The equity has contracted by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.